Tag Archives: Allergan PLC

Senators seek probe of Allergan’s patent sale to Mohawk Tribe; could Tesla do the same with its battery patents?

The News: Four senators are demanding an investigation of Allergan PLC’s (Dublin IRL) first-of-a-kind patent deal with the Saint Regis Mohawk Tribe, alleging the move to protect Restasis is another… Read more »

Amgen, Allergan get nod for Avastin biosim; FDA’s Gottlieb making good on vow to hasten generic approvals, catch the EU.

The News: Amgen Inc. (Thousand Oaks CA) and Allergan PLC (Dublin IRL) said Thursday (September 14, 2017) that the Food and Drug Administration has approved their biosimilar version of Roche… Read more »

Teva stock crashes on 2Q earnings disaster; run for the hills, or buy at fire sale price?

The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »

Update: CDC data say docs still making billions from Pharma, med device companies; my personal take.

The News: It’s been a few years since the US government unveiled its Open Payments (OP) database, a collection of drug and device makers’ payments to healthcare providers. The data-collection… Read more »

Novartis teams up with Allergan in NASH gamble; heated race to riches in full swing

The News: Allergan PLC (Dublin IRL) is expanding its research and development program on non-alcoholic steatohepatitis (NASH) through a collaboration with Novartis AG (Basel CHE) that will test a new… Read more »

Week’s opening stock salvo: Cellect, Impax, Cancer Genetics celebrate; Foamix, not so much

After the resounding thud heard round-the-world Friday upon the failure of Trumpcare, healthcare stocks were back in vogue with investors Monday (March 27, 2017). Here are the top stars and… Read more »

Trump tweet on drug prices sinks pharma shares; what’s next, doctors’ wages? Not.

Steve’s Take: President Trump’s morning ritual continues to enthrall millions, but occasionally causes Wall Street analysts covering the pharma industry to reach for their bottle of Maalox. After House Republicans… Read more »

After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?

Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »

Teva reports 4Q earnings surprise; but 2017 guidance seen “through a glass darkly.”

The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) reported Monday (February 13, 2017) that fourth-quarter sales surged 33% year-over-year to $6.5 billion, topping analysts’ estimates of $6.3 billion. The company… Read more »